Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Identifieur interne : 000421 ( Main/Exploration ); précédent : 000420; suivant : 000422Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Auteurs : A L Marano [États-Unis] ; J M Clarke [États-Unis] ; M A Morse [États-Unis] ; A. Shah [États-Unis] ; W. Barrow [États-Unis] ; M A Selim [États-Unis] ; R P Hall [États-Unis] ; A R Cardones [États-Unis]Source :
- The British journal of dermatology [ 1365-2133 ] ; 2019.
Abstract
Programmed cell death 1 (PD-1) blockade has rapidly emerged as an effective therapy for a wide variety of metastatic malignancies. It has been associated with multiple immune-related adverse effects, including cutaneous eruptions. We describe two patients with clinical and histological findings that were consistent with subacute cutaneous lupus erythematosus (SCLE) after receiving PD-1 inhibitor therapy for metastatic lung cancer. We successfully treated our first patient with systemic and topical steroids, photoprotection and hydroxychloroquine. However, he subsequently developed dermatomyositis after continuing PD-1 inhibitor therapy. Our second patient presented with a protracted course of a cutaneous eruption in spite of discontinuation of anti-PD-1 therapy and treatment with systemic corticosteroids and infliximab. This patient's SCLE resolved after the addition of topical steroids and photoprotection and discontinuation of anti-tumour necrosis factor therapy. She and her oncology team decided to pursue non-PD-1 inhibitor treatment for lung cancer owing to a lack of tumour response. We add SCLE and dermatomyositis to the growing list of autoimmune complications of PD-1 blockade. Our cases raise a number of questions, particularly in relation to the viability of continuing anti-PD-1 therapy after developing SCLE and the role of immunosuppressive therapy in patients with PD-1 inhibitor-associated connective tissue disease. What's already known about this topic? Programmed cell death 1 (PD-1) blockade, which is rapidly emerging as a therapy for a wide variety of metastatic malignancies, has been associated with multiple immune-related adverse effects. These include systemic autoimmune diseases such as colitis and thyroiditis in addition to numerous cutaneous adverse events. Cutaneous side-effects of PD-1 inhibitors most commonly reported in clinical trials include lichenoid reactions, eczematous dermatitis and vitiligo. What does this study add? We report two cases of PD-1 inhibitor-associated subacute cutaneous lupus erythematosus (SCLE), with one patient progressing to dermatomyositis with continued PD-1 inhibitor treatment. In addition to being a novel cutaneous adverse event, we also demonstrate the possibility of development of multiple autoimmune diseases in one patient, which is different from classic drug-related SCLE. We discuss the treatment challenges for patients with autoimmune skin disease receiving PD-1 inhibitor therapy.
DOI: 10.1111/bjd.17245
PubMed: 30244487
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000082
- to stream PubMed, to step Curation: 000082
- to stream PubMed, to step Checkpoint: 000029
- to stream Ncbi, to step Merge: 000473
- to stream Ncbi, to step Curation: 000473
- to stream Ncbi, to step Checkpoint: 000473
- to stream Main, to step Merge: 000421
- to stream Main, to step Curation: 000421
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.</title>
<author><name sortKey="Marano, A L" sort="Marano, A L" uniqKey="Marano A" first="A L" last="Marano">A L Marano</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Clarke, J M" sort="Clarke, J M" uniqKey="Clarke J" first="J M" last="Clarke">J M Clarke</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morse, M A" sort="Morse, M A" uniqKey="Morse M" first="M A" last="Morse">M A Morse</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shah, A" sort="Shah, A" uniqKey="Shah A" first="A" last="Shah">A. Shah</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Barrow, W" sort="Barrow, W" uniqKey="Barrow W" first="W" last="Barrow">W. Barrow</name>
<affiliation wicri:level="2"><nlm:affiliation>Ameripath Inc., Palm Beach Gardens, FL, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Ameripath Inc., Palm Beach Gardens, FL</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Selim, M A" sort="Selim, M A" uniqKey="Selim M" first="M A" last="Selim">M A Selim</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hall, R P" sort="Hall, R P" uniqKey="Hall R" first="R P" last="Hall">R P Hall</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cardones, A R" sort="Cardones, A R" uniqKey="Cardones A" first="A R" last="Cardones">A R Cardones</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30244487</idno>
<idno type="pmid">30244487</idno>
<idno type="doi">10.1111/bjd.17245</idno>
<idno type="wicri:Area/PubMed/Corpus">000082</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000082</idno>
<idno type="wicri:Area/PubMed/Curation">000082</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000082</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000029</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000029</idno>
<idno type="wicri:Area/Ncbi/Merge">000473</idno>
<idno type="wicri:Area/Ncbi/Curation">000473</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000473</idno>
<idno type="wicri:Area/Main/Merge">000421</idno>
<idno type="wicri:Area/Main/Curation">000421</idno>
<idno type="wicri:Area/Main/Exploration">000421</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.</title>
<author><name sortKey="Marano, A L" sort="Marano, A L" uniqKey="Marano A" first="A L" last="Marano">A L Marano</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Clarke, J M" sort="Clarke, J M" uniqKey="Clarke J" first="J M" last="Clarke">J M Clarke</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morse, M A" sort="Morse, M A" uniqKey="Morse M" first="M A" last="Morse">M A Morse</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shah, A" sort="Shah, A" uniqKey="Shah A" first="A" last="Shah">A. Shah</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Barrow, W" sort="Barrow, W" uniqKey="Barrow W" first="W" last="Barrow">W. Barrow</name>
<affiliation wicri:level="2"><nlm:affiliation>Ameripath Inc., Palm Beach Gardens, FL, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Ameripath Inc., Palm Beach Gardens, FL</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Selim, M A" sort="Selim, M A" uniqKey="Selim M" first="M A" last="Selim">M A Selim</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hall, R P" sort="Hall, R P" uniqKey="Hall R" first="R P" last="Hall">R P Hall</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cardones, A R" sort="Cardones, A R" uniqKey="Cardones A" first="A R" last="Cardones">A R Cardones</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Dermatology, Duke University Medical Center, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The British journal of dermatology</title>
<idno type="eISSN">1365-2133</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Programmed cell death 1 (PD-1) blockade has rapidly emerged as an effective therapy for a wide variety of metastatic malignancies. It has been associated with multiple immune-related adverse effects, including cutaneous eruptions. We describe two patients with clinical and histological findings that were consistent with subacute cutaneous lupus erythematosus (SCLE) after receiving PD-1 inhibitor therapy for metastatic lung cancer. We successfully treated our first patient with systemic and topical steroids, photoprotection and hydroxychloroquine. However, he subsequently developed dermatomyositis after continuing PD-1 inhibitor therapy. Our second patient presented with a protracted course of a cutaneous eruption in spite of discontinuation of anti-PD-1 therapy and treatment with systemic corticosteroids and infliximab. This patient's SCLE resolved after the addition of topical steroids and photoprotection and discontinuation of anti-tumour necrosis factor therapy. She and her oncology team decided to pursue non-PD-1 inhibitor treatment for lung cancer owing to a lack of tumour response. We add SCLE and dermatomyositis to the growing list of autoimmune complications of PD-1 blockade. Our cases raise a number of questions, particularly in relation to the viability of continuing anti-PD-1 therapy after developing SCLE and the role of immunosuppressive therapy in patients with PD-1 inhibitor-associated connective tissue disease. What's already known about this topic? Programmed cell death 1 (PD-1) blockade, which is rapidly emerging as a therapy for a wide variety of metastatic malignancies, has been associated with multiple immune-related adverse effects. These include systemic autoimmune diseases such as colitis and thyroiditis in addition to numerous cutaneous adverse events. Cutaneous side-effects of PD-1 inhibitors most commonly reported in clinical trials include lichenoid reactions, eczematous dermatitis and vitiligo. What does this study add? We report two cases of PD-1 inhibitor-associated subacute cutaneous lupus erythematosus (SCLE), with one patient progressing to dermatomyositis with continued PD-1 inhibitor treatment. In addition to being a novel cutaneous adverse event, we also demonstrate the possibility of development of multiple autoimmune diseases in one patient, which is different from classic drug-related SCLE. We discuss the treatment challenges for patients with autoimmune skin disease receiving PD-1 inhibitor therapy.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>Floride</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Marano, A L" sort="Marano, A L" uniqKey="Marano A" first="A L" last="Marano">A L Marano</name>
</region>
<name sortKey="Barrow, W" sort="Barrow, W" uniqKey="Barrow W" first="W" last="Barrow">W. Barrow</name>
<name sortKey="Cardones, A R" sort="Cardones, A R" uniqKey="Cardones A" first="A R" last="Cardones">A R Cardones</name>
<name sortKey="Clarke, J M" sort="Clarke, J M" uniqKey="Clarke J" first="J M" last="Clarke">J M Clarke</name>
<name sortKey="Hall, R P" sort="Hall, R P" uniqKey="Hall R" first="R P" last="Hall">R P Hall</name>
<name sortKey="Morse, M A" sort="Morse, M A" uniqKey="Morse M" first="M A" last="Morse">M A Morse</name>
<name sortKey="Selim, M A" sort="Selim, M A" uniqKey="Selim M" first="M A" last="Selim">M A Selim</name>
<name sortKey="Shah, A" sort="Shah, A" uniqKey="Shah A" first="A" last="Shah">A. Shah</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000421 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000421 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:30244487 |texte= Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30244487" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |